Estimates

Source: S&P Capital IQ consensus via Xpressfeed · Generated 2026-07-26.

Vital Farms' consensus tape has been cut hard over the past six months: FY2027 revenue is down about 25% and normalized EPS about 80% versus 180 days ago, though the pace of cuts has slowed in the last month. A long run of large EPS beats broke with two consecutive misses in FY2025 Q4 and FY2026 Q1, and analysts now model a loss-making FY2026 margin trough before a partial FY2027-28 recovery. Coverage thins sharply beyond FY2027, and the street sits mostly at Hold.

Street slashed FY27 EPS ~65% and revenue ~17% over 90 days

The 30-day change is near flat for revenue, so most of the reduction landed one to six months ago rather than recently.

Currency: USD · Scale: money in millions, absolute · Point-in-time consensus; Δ90d is Now versus 90d.

Metric FY 180d 90d 30d Now Δ90d
EPS (normalized) FY2027 $2.16 $1.26 $0.50 $0.44 -64.6%
EPS (normalized) FY2028 $1.07 $0.49 $0.49 -54.2%
Revenue FY2027 $1.14bn $1.02bn $846.92m $848.58m -16.8%
Revenue FY2028 $1.17bn $905.33m $946.40m -18.8%

Six straight EPS beats, then two consecutive misses

Revenue has stayed close to consensus throughout; the swing is concentrated in EPS, where FY2026 Q1 landed well below the estimate.

Current sequences by metric: Revenue: 4 consecutive beats; EPS (normalized): 2 consecutive misses.

Currency: USD · Scale: money in millions, absolute · Consensus is captured before each actual first became effective.

Quarter Metric Consensus Actual Surprise Outcome
Q1 FY2026 Revenue $182.37m $187.16m +2.6% Beat
Q1 FY2026 EPS (normalized) $0.06 -$0.03 -150.8% Miss
Q4 FY2025 Revenue $212.83m $213.55m +0.3% Beat
Q4 FY2025 EPS (normalized) $0.39 $0.35 -11.2% Miss
Q3 FY2025 Revenue $191.43m $198.94m +3.9% Beat
Q3 FY2025 EPS (normalized) $0.30 $0.36 +20.0% Beat
Q2 FY2025 Revenue $170.81m $184.77m +8.2% Beat
Q2 FY2025 EPS (normalized) $0.27 $0.36 +31.7% Beat
Q1 FY2025 Revenue $162.98m $162.19m -0.5% Miss
Q1 FY2025 EPS (normalized) $0.26 $0.37 +43.0% Beat
Q4 FY2024 Revenue $160.32m $165.99m +3.5% Beat
Q4 FY2024 EPS (normalized) $0.17 $0.23 +39.4% Beat
Q3 FY2024 Revenue $145.30m $145.00m -0.2% Miss
Q3 FY2024 EPS (normalized) $0.12 $0.16 +33.3% Beat
Q2 FY2024 Revenue $138.42m $147.39m +6.5% Beat
Q2 FY2024 EPS (normalized) $0.20 $0.36 +81.8% Beat

Consensus models a FY26 loss-year margin trough, then recovery

Gross margin is modelled to fall from about 38% in FY2025 to about 26% in FY2026 before rebuilding toward roughly 33% by FY2028.

Currency: USD · Scale: money in millions, absolute · YoY uses the prior fiscal year from the feed; analyst count and range use the first displayed period.

Metric FY2025A FY2026E FY2027E FY2028E YoY Analysts Low / high
Revenue $758.94m $775.31m $848.58m $946.40m 11 $755.00m / $761.60m
Gross margin 37.9% 25.6% 29.7% 33.0%
EPS (normalized) $1.48 -$0.42 $0.44 $0.49 10 $1.45 / $1.50
EBITDA $115.37m $3.42m $45.67m $74.00m 12 $115.00m / $116.00m

Wide FY27 dispersion: EPS $0.21-$0.90, EBITDA $10m-$65m

Coverage is deepest at FY2027, yet the ranges frame an unresolved debate over how far and how fast margins recover.

Currency: USD · Scale: money in millions, absolute · Spread/mean is absolute high-low divided by absolute mean.

Metric Period Mean Low–high Spread/mean Analysts
EPS (normalized) FY2027E $0.44 $0.21–$0.90 155.3% 7
EBITDA FY2027E $45.67m $10.06m–$64.90m 120.1% 9
Revenue FY2027E $848.58m $798.70m–$987.00m 22.2% 10

Mostly Hold - 7 of 10 neutral, no sells; targets $10-$16

Currency: USD · Scale: money in millions, absolute · Analyst counts shown explicitly.

Street view Reading Analysts
Recommendation mix Buy 2, Outperform 1, Hold 7, Underperform 0, Sell 0 10
Consensus score 2.50 10
Target price mean $12.00; median $12.00; high $16.00; low $10.00 8

FY2028 rests on just one or two analysts

FY2028 revenue, EPS and net income each rest on a single estimate, and EBITDA on two; treat the outer year as indicative, not consensus.